Iqvia Hldgs Inc Stock Price, News & Analysis

IQVIA (NYSE:IQV) reported strong Q1 2025 financial results with revenue reaching $3,829 million, up 2.5% reported and 3.5% at constant currency. The company posted GAAP Net Income of $249 million and Adjusted EBITDA of $883 million, up 2.4% year-over-year. Technology & Analytics Solutions (TAS) revenue grew 7.6% at constant currency to $1,546 million, while R&D Solutions achieved $2.1 billion in quarterly bookings with a backlog of $31.5 billion. The company demonstrated strong cash management with Operating Cash Flow of $568 million and Free Cash Flow of $426 million, up 13% year-over-year. IQVIA repurchased $425 million of common stock and raised its full-year 2025 revenue guidance to $16,000-$16,400 million, while maintaining profit guidance with Adjusted EBITDA of $3,765-$3,885 million.

IQVIA (NYSE:IQV) announced that two of its executives have received prestigious Healthcare Businesswomen's Association (HBA) awards. Marie E. Lamont, head of Real World Solutions, has been named a Luminary, while Dr. Joanne Hackett, vice president of Health System Services, has been recognized as a Rising Star.

Lamont was recognized for enhancing patient voice in research and advancing women in healthcare. Since joining through the Inteliquet acquisition in 2021, she has led 800 colleagues across the U.S., India, and Europe, significantly improving operational performance. Hackett was honored for her scientific leadership, establishing key UK healthcare institutions, and revolutionizing IQVIA's precision medicine and genomics strategy.

Both executives will be celebrated at HBA's Woman of the Year Annual celebration in Chicago on May 9, 2025.

IQVIA (NYSE:IQV) has been recognized as a 'front-runner generative AI leader' for the life sciences industry by Everest Group® in their report 'AI-deas to Action: Operationalizing Generative AI in Life Sciences.' IQVIA stands out as the only clinical research organization (CRO) to achieve the highest front-runner ranking among 15 evaluated companies.

The company's Healthcare-grade AI® solutions have demonstrated leadership in integrating generative AI capabilities across research and development stages, focusing on patient journey analysis, clinical trial design, product commercialization strategies, and market access insights. IQVIA AI Assistant, their interactive tool for healthcare and life sciences insight generation, recently received the PM360 Innovation Award in the AI Category.

IQVIA Holdings (NYSE:IQV) has scheduled its first-quarter 2025 financial results announcement for Tuesday, May 6, 2025, before market opening. The management team will host a conference call and webcast at 9:00 a.m. Eastern Time on the same day.

The earnings release and financial information will be available on IQVIA's Investor Relations website. Interested parties must pre-register for the conference call through a provided link, after which they will receive confirmation details including a unique passcode and registrant ID. A webcast replay will be accessible approximately two hours after the event concludes.

Biopharma R&D showed significant progress in 2024, with funding reaching a 10-year high of $102 billion, excluding pandemic peaks - a substantial increase from $71 billion in 2023. Clinical trial starts stabilized at 5,318, comparable to pre-pandemic levels of 5,316 in 2019.

The year saw 65 novel active substances launched globally, including breakthrough treatments in schizophrenia, MASH, rare neurological diseases, and non-oncology hematology. While this represents a decline from 80 launches in 2023, it surpasses pre-pandemic figures.

Notable improvements include increased Phase III trial success rates, though Phase I and II success rates declined. Inter-trial intervals improved to 17 months from the 2022 pandemic peak of 32 months. Companies are implementing productivity enablers including decision frameworks, clinical technologies, and artificial intelligence solutions to address R&D complexity amid economic and geopolitical challenges.

IQVIA (NYSE:IQV) has been recognized as a leader in the IDC MarketScape's 2024 assessment for decentralized clinical trial (DCT) technologies and consulting services. The company's leadership position is attributed to its extensive network of over 200 DCT consultants, comprehensive DCT-enabling technologies, and expertise in regulatory strategy implementation.

IDC's first assessment of DCT technology solutions highlights IQVIA's strengths in:

• Deep clinical and DCT implementation strategy expertise across therapeutic areas
• Healthcare-grade AI implementation across the value chain
• Novel GenAI tools for enhanced patient experience
• Country-wise regulatory strategy expertise

Decentralized clinical trials, which gained momentum during COVID-19, utilize telemedicine and mobile technologies to conduct trial activities remotely. This approach enables patient monitoring through wearable devices and digital tools, reducing the need for in-person site visits.

IQVIA Laboratories has launched Site Lab Navigator, an advanced solution suite featuring innovative e-Requisition technology to streamline clinical trial lab workflows. The new system enables electronic submission of requisitions and lab specimen management, replacing manual paper processes.

Key features include:

• Seamless portal integration via IQVIA's One Home for Sites™
• Real-time sample tracking with courier data
• Guided kit replacement and online order management
• Real-time data validation
• Guided data entry to reduce errors
• Online sample collection guidance

Several top 10 pharmaceutical companies have already adopted the platform, which aims to reduce site administrative burden, improve data integrity, and accelerate trial outcomes through automated workflows and real-time data validation.

IQVIA AI Assistant has been awarded the 2024 PM360 Innovation Award in the Artificial Intelligence category. Launched in September 2024, this revolutionary tool provides quick, precise answers to complex business questions through a conversational interface with advanced data science capabilities.

The AI Assistant builds on IQVIA's decade-long experience in artificial intelligence and Healthcare-grade AI™, which prioritizes data privacy, security, and regulatory compliance. Currently available solutions include IQVIA Orchestrated Analytics with AI Assistant and IQVIA ChannelDynamics® Verbatim with AI Assistant, with additional offerings planned for launch this year.

These solutions help life sciences companies integrate AI-driven insights into strategic decision-making, enhancing precision and efficiency in commercial analytics and market research. The recognition from PM360, a leading pharmaceutical industry journal, validates IQVIA's commitment to delivering AI solutions that maintain high standards of trust, scalability, and precision.

IQVIA Holdings (NYSE:IQV) has announced that Ron Bruehlman, executive vice president and chief financial officer, will be presenting at the TD Cowen Annual Health Care Conference. The presentation is scheduled for Tuesday, March 4, 2025, at 11:10 a.m. ET.

Investors and interested parties can access a live audio webcast of the presentation through IQVIA's Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be made available following the presentation on the same day.